CEL-SCI Corp
$ 4.95
6.68%
17 Apr - close price
- Market Cap 41,866,900 USD
- Current Price $ 4.95
- High / Low $ 4.95 / 4.66
- Stock P/E N/A
- Book Value 1.38
- EPS -3.95
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.60 %
- ROE -2.12 %
- 52 Week High 13.48
- 52 Week Low 1.98
About
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Analyst Target Price
$25.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-17 | 2025-12-23 | 2025-08-12 | 2025-05-13 | 2025-01-13 | 2024-12-31 | 2024-08-14 | 2024-05-15 | 2024-02-14 | 2023-12-21 | 2023-08-10 | 2023-05-12 |
| Reported EPS | -0.68 | -0.86 | -1.36 | -2.3323 | -2.7 | -2.7003 | -0.14 | -0.14 | -0.14 | -0.16 | -0.19 | -0.19 |
| Estimated EPS | 0 | None | None | None | -3.3 | -0.1 | -0.13 | -0.14 | -0.14 | -0.16 | -0.16 | -0.17 |
| Surprise | -0.68 | 0 | 0 | 0 | 0.6 | -2.6003 | -0.01 | 0 | 0 | 0 | -0.03 | -0.02 |
| Surprise Percentage | None% | None% | None% | None% | 18.1818% | -2600.3% | -7.6923% | 0% | 0% | 0% | -18.75% | -11.7647% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CVM
2026-04-17 21:09:59
CEL-SCI Corporation is seeking to raise approximately $13.7 million through a "best efforts" offering of common stock and pre-funded warrants to fund the continued development of its lead cancer immunotherapy, Multikine. The company, which reported a net loss of $25.4 million in fiscal 2025 and has concerns about its going concern status, plans to use the proceeds primarily for Multikine's confirmatory registration study and general corporate purposes. This offering is expected to significantly dilute existing shareholders, increasing outstanding shares from 8.49 million to 11.93 million.
2026-04-01 15:10:40
CEL-SCI Corp's Chief Financial Officer, Patricia B. Prichep, was granted 1,336 shares of Common Stock on March 31, 2026, as reported in a Form 4 filing. This equity award, valued at $3.21 per share, increases her direct holdings to 13,364 shares and is considered a routine compensation-related transaction. The filing provides transparent details about insider trading activity for investors.
2026-04-01 15:10:40
CEL SCI CEO Geert R. Kersten was awarded 1,682 shares of common stock on March 31, 2026, valued at $3.21 per share. This stock grant increased his direct holdings to 122,497 common shares. The transaction, reported in a Form 4 SEC filing, represents an equity-based compensation rather than an open-market purchase.
2026-04-01 11:09:40
CEL SCI CORP's Chief Scientific Officer, Talor Eyal, acquired 747 shares of Common Stock on March 31, 2026, through a grant or award. The acquisition was valued at $3.21 per share, increasing Eyal's direct holdings to 7,011 shares. This transaction was reported in a Form 4 filing with the SEC, indicating a neutral impact and sentiment.
2026-04-01 09:10:40
This article provides a technical analysis of CEL-SCI Corp (CVM) as of April 1, 2026, indicating an overall "Sell" consensus based on various technical indicators. It details momentum indicators like RSI and MACD, support and resistance levels, and analyzes the stock's performance relative to its moving averages. The analysis suggests that CVM is currently in neutral RSI territory but shows strong "Sell" signals from MACD and its position below key moving averages.
2026-03-23 13:10:30
This article analyzes the historical performance of a $1,000 investment in CEL-SCI Corp (CVM) over various periods, showing significant losses over the last five and ten years, while briefly detailing the company's focus on cancer immunotherapy and its lead product, Multikine. It also highlights CEL-SCI's ongoing regulatory efforts in the U.S. and Saudi Arabia and its financial status as a clinical-stage biotechnology company.
